| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $1.40B | +37.6% |
| Cost of Revenue | $228.8M | +43.5% |
| R&D Expense | $81.5M | +3.1% |
| SG&A Expense | $207.1M | +34.2% |
| Operating Income | $469.0M | -15.0% |
| Pre-tax Income | $466.9M | -16.2% |
| Income Tax | $150.0M | +32.7% |
| Net Income | $316.9M | -28.6% |
| EPS (Basic) | $2.64 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $133.8M | +15.5% |
| Accounts Receivable | $426.3M | +47.9% |
| Inventory | $176.5M | +24.4% |
| Current Assets | $825.2M | -24.0% |
| Total Assets | $2.53B | +22.4% |
| Current Liabilities | $177.1M | +27.3% |
| Long-term Debt | $2.14B | +42.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $651.6M | +36.0% |
| Capital Expenditures | $7.0M | -34.8% |
| Investing Cash Flow | -$545.8M | -107.8% |
| Financing Cash Flow | -$85.2M | +61.1% |
| Free Cash Flow | $644.6M | +37.6% |
| -24.6% |
| EPS (Diluted) | $2.56 | -25.4% |
| Total Liabilities |
| $2.48B |
| +45.7% |
| Stockholders' Equity | $48.8M | -86.6% |